C5 and chronic inflammatory demyelinating polyradiculoneuropathy: However, IVIG treatment in CIDP patients did not result in any change of C3a, C5a or terminal complement complexes when compared to the placebo group, thus showing that IVIG treatment does not modulate complement deposition or pathway [220].